This combination may lead to acquisition of additional somatic mutations (e.g., in SUZ12 or ASXL1) or chromosomal abnormalities (e.g., monosomy 7 or trisomy 21), which finally overt to MDS or AML (Fig. 4). This evidence concerns the gene ASXL1 and acute myeloid leukemia.